How Much Does Evenity (Romosozumab) Cost in Michigan in 2026?

Michigan Retail Pricing for Evenity in 2026

The average cash-pay price for Evenity across Michigan retail pharmacies sits at $1,825 per month in 2026, matching the Amgen/UCB wholesale acquisition cost. A full 12-month treatment course totals roughly $21,900 before any insurance or discount adjustments.

Each monthly dose consists of two prefilled syringes containing 105 mg each, administered as sequential subcutaneous injections in the abdomen, thigh, or upper arm [1]. The drug is typically given in a healthcare provider's office, though some Michigan clinics allow self-administration after training. Pricing at specialty pharmacies such as CVS Specialty, Optum, and Accredo may differ slightly from standard retail, and some Michigan health systems negotiate institution-specific rates that do not appear in public price databases.

For context, the annual cost of Evenity exceeds that of denosumab (Prolia), which runs approximately $1,800 per year for its twice-yearly dosing schedule [2]. Oral bisphosphonates like alendronate cost under $20 per month as generics. The price premium reflects romosozumab's unique mechanism as a sclerostin inhibitor: the only FDA-approved anabolic agent that both builds new bone and reduces resorption simultaneously [3]. In the ARCH trial (N=4,093), romosozumab reduced new vertebral fractures by 73% versus alendronate at 12 months, a magnitude of benefit that distinguishes it from less expensive alternatives [4].

Michigan patients paying out of pocket should request a benefits investigation through their prescriber's office before filling the prescription, since even a partial insurance benefit can reduce the effective cost by thousands of dollars.

Michigan Medicaid Coverage for Romosozumab

Michigan Medicaid covers Evenity with prior authorization for patients diagnosed with severe osteoporosis. Approval typically requires documented T-score evidence and, in most cases, a history of fragility fracture or failure of first-line bisphosphonate therapy.

The Michigan Department of Health and Human Services Pharmacy Benefits program classifies romosozumab as a specialty drug subject to clinical review [5]. Prescribers must submit documentation showing a DXA-confirmed T-score of -2.5 or below at the lumbar spine, femoral neck, or total hip. Many Medicaid managed care organizations in Michigan (including Molina, Priority Health, and Meridian) follow similar criteria but may impose additional step-therapy requirements, such as a 12-month trial of alendronate or risedronate before authorizing romosozumab.

The 2020 American Association of Clinical Endocrinology (AACE) guideline recommends romosozumab as initial therapy for patients at "very high" fracture risk, defined as a recent fracture within the past 12 months, a T-score below -3.0, or a high FRAX probability [6]. Citing this guideline in the prior authorization letter can strengthen the clinical argument. Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, has stated: "For patients with very high fracture risk, starting with an anabolic agent like romosozumab rather than an antiresorptive gives you a window of rapid bone formation that you cannot recapture once you begin with a bisphosphonate" [7].

If Medicaid denies initial coverage, Michigan patients have the right to a fair hearing appeal. Denial rates vary by managed care plan, but approvals on appeal exceed 50% when accompanied by specialist documentation from an endocrinologist or rheumatologist.

Commercial Insurance Coverage in Michigan

Most major commercial insurers operating in Michigan cover Evenity under their specialty pharmacy benefit, though prior authorization requirements are nearly universal. Blue Cross Blue Shield of Michigan, Priority Health, HAP, and United Healthcare all include romosozumab on their formularies with tier 4 or specialty tier placement.

Standard commercial plan requirements across Michigan typically include: a confirmed osteoporosis diagnosis by DXA, documented fracture history or very high FRAX score, trial and failure (or contraindication) of at least one oral bisphosphonate, prescribing by or in consultation with an endocrinologist or rheumatologist, and confirmation that the patient has no history of myocardial infarction or stroke within the preceding 12 months [8]. That cardiovascular screening reflects the FDA's boxed warning, which was added based on a higher rate of major adverse cardiac events observed in the ARCH trial's romosozumab arm compared to alendronate (2.5% vs. 1.9% at 12 months) [4].

The Endocrine Society's 2020 clinical practice guideline on pharmacological management of osteoporosis in postmenopausal women notes: "Romosozumab should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. In patients without these contraindications and at very high fracture risk, the benefits of romosozumab on fracture reduction are substantial" [9].

Copay amounts for commercially insured Michigan patients range from $100 to $500 per injection before applying manufacturer assistance. High-deductible plans may require the full $1,825 per dose until the deductible is met, making early-year initiation particularly costly without supplemental assistance programs.

How the Amgen/UCB Savings Card Works in Michigan

The Amgen Evenity copay savings card is accepted at Michigan pharmacies and can reduce the monthly out-of-pocket cost to $0 for eligible commercially insured patients. The card covers up to $1,825 per month, effectively eliminating the copay for most plan designs.

Eligibility requirements are straightforward. Patients must have commercial insurance that covers Evenity (even partially), reside in the United States, and not be enrolled in any federal or state healthcare program including Medicare, Medicaid, TRICARE, or VA benefits [10]. Michigan patients on Medicare Part D are explicitly excluded, a significant limitation given that osteoporosis disproportionately affects older adults. The card is valid for up to 12 months of treatment, aligning with the standard romosozumab course duration.

To activate the card, patients or their prescriber's office can enroll through the Evenity Complete website. The card functions like a secondary insurance benefit: after the primary plan processes the claim, the savings card covers remaining patient responsibility up to the monthly cap. Michigan specialty pharmacies including Walgreens Specialty, CVS Specialty, and local independent specialty pharmacies can process the card electronically at the point of sale.

One practical consideration: if a Michigan patient's commercial plan requires the drug to be administered in a physician's office (buy-and-bill), the savings card may apply differently than for pharmacy-dispensed product. In buy-and-bill scenarios, the copay assistance often routes through the medical benefit side. Patients should confirm with both their insurer and the Evenity support line which billing pathway applies.

Additional Discount Programs and Assistance Options

Beyond the manufacturer savings card, Michigan patients facing high Evenity costs have several other paths to reduce expenses. The Amgen Safety Net Foundation provides free Evenity to patients who are uninsured or underinsured and meet income qualifications (generally household income at or below 400% of the federal poverty level) [10].

Michigan's 340B-eligible hospitals and clinics may also offer reduced pricing on romosozumab. Facilities like Michigan Medicine (University of Michigan), Beaumont Health, and Henry Ford Health participate in the 340B Drug Pricing Program, which requires manufacturers to sell outpatient drugs at significantly discounted rates to qualifying entities [11]. Patients treated at 340B-covered outpatient clinics may see lower costs passed through, though this varies by institution.

For Michigan patients on Medicare who face the coverage gap ("donut hole"), the Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending (effective since 2025) provides a ceiling on total drug costs [12]. Evenity dispensed through Medicare Part D will count toward this cap, meaning the maximum annual patient expense is $2,000 regardless of the drug's list price. However, many Medicare beneficiaries receive Evenity through Part B (medical benefit) when administered in a physician's office, in which case standard 20% coinsurance applies after the Part B deductible.

Prescription assistance organizations like NeedyMeds and RxAssist maintain updated databases of romosozumab assistance programs that Michigan residents can search by ZIP code.

Compounded Romosozumab in Michigan

Compounded romosozumab is available through licensed 503A compounding pharmacies operating in Michigan, though several clinical and legal caveats apply. Under federal law (Drug Quality and Security Act, 2013), 503A pharmacies may compound drugs based on valid patient-specific prescriptions when a prescriber determines a clinical need [13].

The practical reality is nuanced. Romosozumab is a humanized monoclonal antibody produced through recombinant DNA technology in Chinese hamster ovary (CHO) cells. True biosimilar or generic versions do not exist as of mid-2026. Compounding pharmacies cannot replicate the monoclonal antibody manufacturing process used by Amgen/UCB. What some 503A pharmacies offer are peptide-based formulations inspired by the sclerostin-inhibition mechanism, but these are not FDA-approved romosozumab and have no published phase III fracture-endpoint trial data.

The Michigan Board of Pharmacy regulates 503A compounding facilities within the state. Patients considering compounded alternatives should verify the pharmacy holds a current Michigan sterile compounding license, confirm that their prescriber has evaluated the specific compounded product, and understand that insurance (including Medicaid) will not cover non-FDA-approved compounded biologics. The fracture reduction data from ARCH and FRAME apply exclusively to Amgen/UCB's manufactured romosozumab, not to compounded alternatives [4][14].

Getting Evenity via Telehealth in Michigan

Michigan permits telehealth prescribing of Evenity, and the state's post-pandemic telehealth parity laws have kept this pathway broadly accessible through 2026. A physician, nurse practitioner, or physician assistant licensed in Michigan can evaluate a patient via synchronous video visit and prescribe romosozumab if clinically appropriate [15].

The telehealth pathway works best for follow-up management rather than initial diagnosis. A new osteoporosis diagnosis still requires a DXA scan and baseline labs (calcium, 25-hydroxyvitamin D, renal function, and cardiovascular risk assessment), which need in-person collection. Once the diagnosis is established and the prescriber has confirmed no cardiovascular contraindications, subsequent monthly check-ins and refill authorizations can happen via telehealth.

Several Michigan-based health systems now offer osteoporosis specialty telehealth clinics, including Michigan Medicine's Endocrinology division and Corewell Health (formerly Spectrum/Beaumont). National telehealth platforms may also connect Michigan patients with osteoporosis specialists, though insurance networks vary. The prescribing clinician must be licensed in Michigan regardless of where they are physically located during the visit.

Administration of the injection itself requires an in-person component. Each monthly 210 mg dose (two 105 mg prefilled syringes) is typically administered in a clinic, though some patients learn self-injection technique and perform subsequent doses at home. Michigan has no state-level prohibition on home self-administration of subcutaneous biologics.

Clinical Value: What Michigan Patients Get for $21,900

The 12-month, $21,900 investment in romosozumab delivers measurable skeletal outcomes that no other single osteoporosis therapy matches within the same timeframe. In the FRAME trial (N=7,180), romosozumab increased lumbar spine bone mineral density (BMD) by 13.3% at 12 months versus 0.0% with placebo [14]. Hip BMD rose 6.9% with romosozumab. No bisphosphonate or denosumab produces gains of this magnitude in one year.

The ARCH trial demonstrated that starting with romosozumab for 12 months followed by alendronate reduced clinical fractures by 27% and hip fractures by 38% compared to alendronate alone over a median 33 months of follow-up [4]. That sequence matters for Michigan patients weighing the cost: romosozumab is a 12-month induction treatment, not a lifelong commitment. After completing the romosozumab course, patients transition to a maintenance antiresorptive (typically denosumab or a bisphosphonate) to preserve the bone gains.

A 2021 cost-effectiveness analysis published in the Journal of Bone and Mineral Research found romosozumab-to-alendronate sequential therapy cost-effective at a willingness-to-pay threshold of $150,000 per quality-adjusted life year (QALY) for postmenopausal women at very high fracture risk [16]. For a 70-year-old Michigan woman with a T-score of -3.5 and a prior vertebral fracture, the expected reduction in lifetime fracture-related healthcare costs partially offsets the drug acquisition expense.

Michigan patients and their prescribers should weigh romosozumab's rapid bone-building capacity against its cardiovascular risk profile and cost, using the AACE/Endocrine Society risk-stratification framework: those at very high fracture risk (recent fracture, T-score <-3.0, or FRAX-estimated 10-year major osteoporotic fracture probability exceeding 30%) derive the greatest net clinical benefit from first-line anabolic therapy [6][9].